Comparative Pharmacology
Head-to-head clinical analysis: RENFLEXIS versus YUSIMRY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RENFLEXIS versus YUSIMRY.
RENFLEXIS vs YUSIMRY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Renflexis (infliximab-abda) is a chimeric monoclonal antibody that binds with high affinity to tumor necrosis factor alpha (TNFα), neutralizing its pro-inflammatory activity. It inhibits TNFα binding to its receptors (TNFR1 and TNFR2), reducing inflammatory cell migration, cytokine production, and tissue damage.
YUSIMRY (adalimumab-adbm) is a tumor necrosis factor (TNF) blocker. It binds to TNF-alpha and neutralizes its activity, reducing inflammatory responses.
5 mg/kg intravenously over at least 2 hours at 0, 2, and 6 weeks, then every 8 weeks.
Subcutaneous: 200 mg every 2 weeks. For patients with body weight ≥100 kg, consider 200 mg every week. IV: 300 mg as a loading dose on day 1, then 200 mg every 2 weeks subcutaneously.
None Documented
None Documented
Terminal elimination half-life approximately 18-21 days (mean ~20 days) in patients with rheumatoid arthritis; supports every-8-week dosing interval.
Terminal elimination half-life ranges from 10 to 20 days (mean ~14 days) in adults; consistent with IgG1 monoclonal antibody clearance. Reduced half-life may be observed in patients with high tumor burden or concomitant methotrexate.
Primarily eliminated via reticuloendothelial system degradation; renal excretion accounts for <1% of dose as unchanged drug; no significant biliary or fecal excretion.
Elimination occurs via reticuloendothelial system with catabolism into amino acids; no significant renal or biliary excretion of intact adalimumab. Mean renal excretion of adalimumab is <1% of dose as intact monoclonal antibody.
Category C
Category C
TNF-alpha Inhibitor
TNF-alpha Inhibitor